Back to top
more

Benitec Biopharma (BNTC)

(Delayed Data from NSDQ)

$11.53 USD

11.53
45,701

-0.10 (-0.82%)

Updated Aug 5, 2025 04:00 PM ET

After-Market: $11.59 +0.07 (0.56%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (143 out of 246)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Is Cintas (CTAS) Stock Outpacing Its Business Services Peers This Year?

by Zacks Equity Research

Here is how Cintas (CTAS) and H20 (HTO) have performed compared to their sector so far this year.

Zacks Equity Research

Are Basic Materials Stocks Lagging Harmony Gold (HMY) This Year?

by Zacks Equity Research

Here is how Harmony Gold (HMY) and Fresnillo PLC (FNLPF) have performed compared to their sector so far this year.

Zacks Equity Research

Is Ardagh Metal Packaging (AMBP) Stock Outpacing Its Industrial Products Peers This Year?

by Zacks Equity Research

Here is how Ardagh Metal Packaging S.A. (AMBP) and Atlas Copco AB (ATLKY) have performed compared to their sector so far this year.

Zacks Equity Research

Is Root (ROOT) Stock Outpacing Its Finance Peers This Year?

by Zacks Equity Research

Here is how Root, Inc. (ROOT) and Banco De Chile (BCH) have performed compared to their sector so far this year.

Zacks Equity Research

Are Utilities Stocks Lagging CenterPoint Energy (CNP) This Year?

by Zacks Equity Research

Here is how CenterPoint Energy (CNP) and Energias de Portugal (EDPFY) have performed compared to their sector so far this year.

Zacks Equity Research

Is McKesson (MCK) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how McKesson (MCK) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Zacks Equity Research

Are Auto-Tires-Trucks Stocks Lagging Aisin Seiki (ASEKY) This Year?

by Zacks Equity Research

Here is how Aisin Seiki Co. Ltd. Unsponsored ADR (ASEKY) and Michelin (MGDDY) have performed compared to their sector so far this year.

Zacks Equity Research

Are Consumer Staples Stocks Lagging Ahold (ADRNY) This Year?

by Zacks Equity Research

Here is how Ahold NV (ADRNY) and Embotelladora Andina S.A. (AKO.B) have performed compared to their sector so far this year.

Zacks Equity Research

Has Karooooo (KARO) Outpaced Other Computer and Technology Stocks This Year?

by Zacks Equity Research

Here is how Karooooo Ltd. (KARO) and Allegro MicroSystems, Inc. (ALGM) have performed compared to their sector so far this year.

Zacks Equity Research

Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

If you are looking for stocks that are well positioned to maintain their recent uptrend, Benitec Biopharma (BNTC) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

Zacks Equity Research

Wall Street Analysts See a 65.98% Upside in Benitec Biopharma (BNTC): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 66% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Is Benitec Biopharma (BNTC) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Benitec Biopharma Limited (BNTC) and Delcath Systems, Inc. (DCTH) have performed compared to their sector so far this year.

Zacks Equity Research

Recent Price Trend in Benitec Biopharma (BNTC) is Your Friend, Here's Why

by Zacks Equity Research

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Wall Street Analysts Think Benitec Biopharma (BNTC) Could Surge 83.91%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Benitec Biopharma (BNTC) points to an 83.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Zacks Equity Research

Are Medical Stocks Lagging Benitec Biopharma (BNTC) This Year?

by Zacks Equity Research

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

Benitec Biopharma (BNTC) Is a Great Choice for 'Trend' Investors, Here's Why

by Zacks Equity Research

Benitec Biopharma (BNTC) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Zacks Equity Research

Is Benitec Biopharma (BNTC) Stock Outpacing Its Medical Peers This Year?

by Zacks Equity Research

Here is how Benitec Biopharma Limited (BNTC) and Concentra Group (CON) have performed compared to their sector so far this year.

Zacks Equity Research

Will Declining Medical Customers Affect Cigna's Q1 Earnings?

by Zacks Equity Research

CI's first-quarter results are likely to have benefited from growing pharmacy revenues and fees.

Zacks Equity Research

Wall Street Analysts Believe Benitec Biopharma (BNTC) Could Rally 84.96%: Here's is How to Trade

by Zacks Equity Research

The consensus price target hints at an 85% upside potential for Benitec Biopharma (BNTC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Zacks Equity Research

What Makes Benitec Biopharma (BNTC) a New Buy Stock

by Zacks Equity Research

Benitec Biopharma (BNTC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

Are Medical Stocks Lagging Ascendis Pharma (ASND) This Year?

by Zacks Equity Research

Here is how Ascendis Pharma A/S (ASND) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Zacks Equity Research

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and Benitec Biopharma Limited (BNTC) have performed compared to their sector so far this year.

Zacks Equity Research

Wall Street Analysts Predict a 127.26% Upside in Benitec Biopharma (BNTC): Here's What You Should Know

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Benitec Biopharma (BNTC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks Equity Research

Benitec Biopharma (BNTC) is on the Move, Here's Why the Trend Could be Sustainable

by Zacks Equity Research

Benitec Biopharma (BNTC) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

Zacks Equity Research

Why You Shouldn't Bet Against Benitec Biopharma (BNTC) Stock

by Zacks Equity Research

Benitec Biopharma (BNTC) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.